Drug intelligence / Profile preview

MK-3120

Development stage: Phase 2
Lead developer: Merck
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MK-3120 (also known as SKB410) is an investigational antibody-drug conjugate (ADC) targeting Nectin-4, a cell adhesion molecule overexpressed in various solid tumors. The drug is being developed for the treatment of advanced malignant solid neoplasms and locally advanced malignant solid neoplasms. Its mechanism involves binding to Nectin-4 on tumor cells and delivering a cytotoxic payload via the ADC modality, leading to targeted cancer cell death. The drug is currently in phase 1/2 clinical trials for oncology indications including advanced and locally advanced solid tumors[1][2][5][6].

Other names: SKB410SKB-410SKB 410

Targets

PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on MK-3120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-3120.

Explore the full profile